Drug-Resistant Shigella Reaches 8.5% in 2023
CDC Alerts Health Officials to Emerging Public Health Threat Across the United States
© CDC / Getty Images – Centers for Disease Control and Prevention
On April 9, 2026, the Centers for Disease Control and Prevention published findings showing that extensively drug-resistant Shigella infections are increasing in the United States. CDC researchers analyzed nearly 17,000 Shigella isolates collected between 2011 and October 2023, revealing a concerning pattern in antimicrobial resistance.
Unlike historical Shigella outbreaks in the United States that primarily affected young children, the latest surveillance data show that most XDR cases occur among adult men, with a median age of 41 years. The bacteria resist five commonly used antibiotics: ampicillin, azithromycin, ceftriaxone, ciprofloxacin, and trimethoprim-sulfamethoxazole. According to the University of Florida Emerging Pathogens Institute, these bacteria require a small infectious dose to cause illness. For more context on related waterborne health issues, see KarmActive’s report on water contamination testing.
The Rising Proportion of Drug-Resistant Cases
The data reveal a clear increase in XDR Shigella over the 2011-2023 period. No XDR cases were identified during 2011-2015. The first XDR Shigella isolates appeared in 2016. From that point forward, the proportion of drug-resistant cases continued to grow. By 2023, nearly one in twelve isolates tested were classified as XDR.
2016: First XDR Shigella isolates identified
2023: Proportion reached 8.5% among isolates tested
How Shigella Spreads Between People
⚕️ Recognizing Symptoms and High-Risk Groups
What to Watch For
- Diarrhea – Often bloody or lasting more than 3 days
- Fever – May occur with infection
- Stomach cramps or pain – Can be severe
- Tenesmus – Feeling of needing to pass stool even when bowels are empty
- Onset: Symptoms typically begin within 1-2 days of infection
- Duration: Usually 5-7 days, though some cases last several weeks or longer
Who Is at Higher Risk
- Adult men – Currently the primary group affected (86.2% of cases)
- People with HIV – 46.6% of patients with available data reported HIV co-infection
- Immunocompromised individuals – Any condition weakening immune response
- International travelers – Especially to areas with poor sanitation
- Men who have sex with men – Sexual transmission risk
- People experiencing homelessness – Limited access to sanitation facilities
Prevention Measures: What You Can Do
Click on each card to learn prevention steps recommended by the CDC. These actions reduce transmission and infection risk.
When to Seek Medical Care
Contact a healthcare provider if you experience:
- Bloody diarrhea or diarrhea lasting more than 3 days
- High fever (103°F / 39.4°C or higher)
- Severe abdominal pain or tenderness
- Signs of dehydration (dark urine, extreme thirst, dizziness)
- Frequent vomiting that prevents drinking fluids
- Being immunocompromised or having HIV
- Symptoms not improving after 7 days
Early medical evaluation can prevent complications and reduce the risk of spreading infection to others.
💬 Understanding XDR Shigella
Dr. Anthony T. Maurelli, a professor of environmental and global health at the University of Florida Emerging Pathogens Institute, describes Shigella as highly efficient at causing disease. The bacteria require only a small infectious dose—as few as 10 organisms—to establish infection.
The CDC emphasizes in their report that “prevention, early detection, antimicrobial susceptibility testing-guided therapy, and timely reporting are important to protect populations at higher risk for XDR Shigella infection.” This multi-layered approach—combining individual prevention with rapid public health response—is essential in the absence of approved oral treatments. For more on related disease outbreaks, see KarmActive’s report on dysentery cases in Portland.
📚 Official Resources and Primary Sources
-
CDC Morbidity and Mortality Weekly Report – April 9, 2026
Official surveillance report analyzing 16,788 Shigella isolates. Direct source for epidemiological data, demographics, and hospitalization rates.
-
CDC – About Shigella Infection
Comprehensive CDC resource covering transmission, symptoms, risk groups, and prevention recommendations.
-
CDC – Signs and Symptoms of Shigella
Clinical information on symptom onset, duration, and when to seek medical care.
-
CDC – Clinical Overview for Healthcare Providers
Medical reference for diagnosis, treatment considerations, and antimicrobial resistance patterns.
-
WHO – Shigellosis Fact Sheet
Global health perspective on Shigella epidemiology and public health impact from the World Health Organization.
Looking Forward
The CDC’s April 2026 report documented an increase in XDR Shigella infections from 0% during 2011-2015 to 8.5% in 2023. The report also noted a shift in epidemiology, with most cases occurring among adult men rather than children as in previous decades. Without FDA-approved oral antimicrobial options, prevention measures and timely reporting remain critical tools for disease control. Hand hygiene, safe food and water practices, and immediate consultation with healthcare providers when symptoms appear are essential steps individuals and communities can take. For the latest public health guidance, visit the CDC’s official website or contact your local health department.
